UPDATE : Friday, December 6, 2019
KangStem Biotech completes stem cell drug plant by Jeong Sae-im 2019-05-16 11:27
Samsung BioLogics in tight spot amid probe, shareholders’ lawsuit by Jeong Sae-im 2019-05-14 14:10
‘MSD Korea’s foreign exec got drunk, sexually harassed female worker’ by Jeong Sae-im 2019-05-14 11:53
Celltrion’s operating income down 33% in Q1 by Jeong Sae-im 2019-05-09 15:26
If Invossa license gets revoked, Kolon should return $13 million to Mundipharma by Jeong Sae-im 2019-05-08 15:33
Mobile healthcare firm Noom raises $58 million for biz expansion by Jeong Sae-im 2019-05-08 15:23
Inspection will clear all suspicions over Invossa: TissueGene by Jeong Sae-im 2019-05-08 14:32
Kolon might have covered up Invossa mislabeling for 2 years by Jeong Sae-im 2019-05-07 15:55
[Exclusive] MSD workers appalled by executive’s remarks on childcare leave by Jeong Sae-im 2019-05-07 12:08
Civic group files complaint against Kolon, regulator by Jeong Sae-im 2019-04-30 14:59
Techniques for biobetters get ever more advanced by Jeong Sae-im 2019-04-29 11:48
‘Invossa scandal might be more far-reaching’ by Jeong Sae-im 2019-04-26 18:08
Foreign patients to join class-action suit against Kolon for Invossa by Jeong Sae-im 2019-04-25 15:39
Samsung Biologics logs ₩23.4 billion operating loss in Q1 by Jeong Sae-im 2019-04-25 12:08
Regulator suspends Eutilex’ trial on cell therapy by Jeong Sae-im 2019-04-23 15:13
Gene therapies’ potentials, challenges explained by Jeong Sae-im 2019-04-22 11:46
Why is TissueGene CEO silent about Invossa mislabeling? by Jeong Sae-im 2019-04-19 14:37
CJ HealthCare’s new gastric acid blocker K-Cab sold ₩ 1.5 billion in March by Jeong Sae-im 2019-04-18 15:27
Patients to file class-action suit against Kolon over Invossa by Jeong Sae-im 2019-04-17 14:58
‘Invossa lacked clinical evidence to be commercialized’ by Jeong Sae-im 2019-04-17 12:45
Back to Top